291 related articles for article (PubMed ID: 28423358)
1. Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypes.
Earp MA; Raghavan R; Li Q; Dai J; Winham SJ; Cunningham JM; Natanzon Y; Kalli KR; Hou X; Weroha SJ; Haluska P; Lawrenson K; Gayther SA; Wang C; Goode EL; Fridley BL
Oncotarget; 2017 Jul; 8(29):46891-46899. PubMed ID: 28423358
[TBL] [Abstract][Full Text] [Related]
2. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
3. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
4. Involvement of DPP9 in gene fusions in serous ovarian carcinoma.
Smebye ML; Agostini A; Johannessen B; Thorsen J; Davidson B; Tropé CG; Heim S; Skotheim RI; Micci F
BMC Cancer; 2017 Sep; 17(1):642. PubMed ID: 28893231
[TBL] [Abstract][Full Text] [Related]
5. Recurrent BCAM-AKT2 fusion gene leads to a constitutively activated AKT2 fusion kinase in high-grade serous ovarian carcinoma.
Kannan K; Coarfa C; Chao PW; Luo L; Wang Y; Brinegar AE; Hawkins SM; Milosavljevic A; Matzuk MM; Yen L
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1272-7. PubMed ID: 25733895
[TBL] [Abstract][Full Text] [Related]
6. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
[TBL] [Abstract][Full Text] [Related]
7. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
[TBL] [Abstract][Full Text] [Related]
8. ESRRA-C11orf20 is a recurrent gene fusion in serous ovarian carcinoma.
Salzman J; Marinelli RJ; Wang PL; Green AE; Nielsen JS; Nelson BH; Drescher CW; Brown PO
PLoS Biol; 2011 Sep; 9(9):e1001156. PubMed ID: 21949640
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel cyclin gene fusion transcripts in endometrioid ovarian carcinomas.
Agostini A; Brunetti M; Davidson B; Göran Tropé C; Heim S; Panagopoulos I; Micci F
Int J Cancer; 2018 Sep; 143(6):1379-1387. PubMed ID: 29633253
[TBL] [Abstract][Full Text] [Related]
10. Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk.
Chornokur G; Lin HY; Tyrer JP; Lawrenson K; Dennis J; Amankwah EK; Qu X; Tsai YY; Jim HS; Chen Z; Chen AY; Permuth-Wey J; Aben KK; Anton-Culver H; Antonenkova N; Bruinsma F; Bandera EV; Bean YT; Beckmann MW; Bisogna M; Bjorge L; Bogdanova N; Brinton LA; Brooks-Wilson A; Bunker CH; Butzow R; Campbell IG; Carty K; Chang-Claude J; Cook LS; Cramer DW; Cunningham JM; Cybulski C; Dansonka-Mieszkowska A; du Bois A; Despierre E; Dicks E; Doherty JA; Dörk T; Dürst M; Easton DF; Eccles DM; Edwards RP; Ekici AB; Fasching PA; Fridley BL; Gao YT; Gentry-Maharaj A; Giles GG; Glasspool R; Goodman MT; Gronwald J; Harrington P; Harter P; Hein A; Heitz F; Hildebrandt MA; Hillemanns P; Hogdall CK; Hogdall E; Hosono S; Jakubowska A; Jensen A; Ji BT; Karlan BY; Kelemen LE; Kellar M; Kiemeney LA; Krakstad C; Kjaer SK; Kupryjanczyk J; Lambrechts D; Lambrechts S; Le ND; Lee AW; Lele S; Leminen A; Lester J; Levine DA; Liang D; Lim BK; Lissowska J; Lu K; Lubinski J; Lundvall L; Massuger LF; Matsuo K; McGuire V; McLaughlin JR; McNeish I; Menon U; Milne RL; Modugno F; Moysich KB; Ness RB; Nevanlinna H; Eilber U; Odunsi K; Olson SH; Orlow I; Orsulic S; Weber RP; Paul J; Pearce CL; Pejovic T; Pelttari LM; Pike MC; Poole EM; Risch HA; Rosen B; Rossing MA; Rothstein JH; Rudolph A; Runnebaum IB; Rzepecka IK; Salvesen HB; Schernhammer E; Schwaab I; Shu XO; Shvetsov YB; Siddiqui N; Sieh W; Song H; Southey MC; Spiewankiewicz B; Sucheston L; Teo SH; Terry KL; Thompson PJ; Thomsen L; Tangen IL; Tworoger SS; van Altena AM; Vierkant RA; Vergote I; Walsh CS; Wang-Gohrke S; Wentzensen N; Whittemore AS; Wicklund KG; Wilkens LR; Wu AH; Wu X; Woo YL; Yang H; Zheng W; Ziogas A; Hasmad HN; Berchuck A; ; ; Iversen ES; Schildkraut JM; Ramus SJ; Goode EL; Monteiro AN; Gayther SA; Narod SA; Pharoah PD; Sellers TA; Phelan CM
PLoS One; 2015; 10(6):e0128106. PubMed ID: 26091520
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma.
Zhang W; Niu C; He W; Hou T; Sun X; Xu L; Zhang Y
Tumour Biol; 2016 May; 37(5):6239-54. PubMed ID: 26615423
[TBL] [Abstract][Full Text] [Related]
12. Long non-coding RNA CCAT1 promotes metastasis and poor prognosis in epithelial ovarian cancer.
Cao Y; Shi H; Ren F; Jia Y; Zhang R
Exp Cell Res; 2017 Oct; 359(1):185-194. PubMed ID: 28754469
[TBL] [Abstract][Full Text] [Related]
13. Identification of two poorly prognosed ovarian carcinoma subtypes associated with CHEK2 germ-line mutation and non-CHEK2 somatic mutation gene signatures.
Ow GS; Ivshina AV; Fuentes G; Kuznetsov VA
Cell Cycle; 2014; 13(14):2262-80. PubMed ID: 24879340
[TBL] [Abstract][Full Text] [Related]
14. Subtype specific elevated expression of hyaluronidase-1 (HYAL-1) in epithelial ovarian cancer.
Yoffou PH; Edjekouane L; Meunier L; Tremblay A; Provencher DM; Mes-Masson AM; Carmona E
PLoS One; 2011; 6(6):e20705. PubMed ID: 21695196
[TBL] [Abstract][Full Text] [Related]
15. Differential MicroRNA Expression Profiles in Primary and Recurrent Epithelial Ovarian Cancer.
Chong GO; Jeon HS; Han HS; Son JW; Lee YH; Hong DG; Lee YS; Cho YL
Anticancer Res; 2015 May; 35(5):2611-7. PubMed ID: 25964536
[TBL] [Abstract][Full Text] [Related]
16. Correlations among ERCC1, XPB, UBE2I, EGF, TAL2 and ILF3 revealed by gene signatures of histological subtypes of patients with epithelial ovarian cancer.
Guo Y; Fu P; Zhu H; Reed E; Remick SC; Petros W; Mueller MD; Yu JJ
Oncol Rep; 2012 Jan; 27(1):286-92. PubMed ID: 21971700
[TBL] [Abstract][Full Text] [Related]
17. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of microRNA-196b Accelerates Invasiveness of Cancer Cells in Recurrent Epithelial Ovarian Cancer Through Regulation of Homeobox A9.
Chong GO; Jeon HS; Han HS; Son JW; Lee YH; Hong DG; Park HJ; Lee YS; Cho YL
Cancer Genomics Proteomics; 2017; 14(2):137-141. PubMed ID: 28387653
[TBL] [Abstract][Full Text] [Related]
19. Modelling genetic and clinical heterogeneity in epithelial ovarian cancers.
Lawrenson K; Sproul D; Grun B; Notaridou M; Benjamin E; Jacobs IJ; Dafou D; Sims AH; Gayther SA
Carcinogenesis; 2011 Oct; 32(10):1540-9. PubMed ID: 21859834
[TBL] [Abstract][Full Text] [Related]
20. Molecular diagnosis in type I epithelial ovarian cancer.
Sadłecki P; Walentowicz-Sadłecka M; Grabiec M
Ginekol Pol; 2017; 88(12):692-697. PubMed ID: 29303228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
